Dopamine Release from Transplanted Neural Stem Cells in Parkinsonian Rat Striatum in Vivo.
Xinjiang Kang,Huadong Xu,Sasa Teng,Xiaoyu Zhang,Zijun Deng,Li Zhou,Panli Zuo,Bing Liu,Bin Liu,Qihui Wu,Li Wang,Meiqin Hu,Haiqiang Dou,Wei Liu,Feipeng Zhu,Qing Li,Shu Guo,Jingli Gu,Qian Lei,Jing Lu,Yu Mu,Mu Jin,Shirong Wang,Wei Jiang,Kun Liu,Changhe Wang,Wenlin Li,Kang Zhang,Zhuan Zhou
DOI: https://doi.org/10.1073/pnas.1408484111
2014-01-01
Abstract:Embryonic stem cell-based therapies exhibit great potential for the treatment of Parkinson's disease (PD) because they can significantly rescue PD-like behaviors. However, whether the transplanted cells themselves release dopamine in vivo remains elusive. We and others have recently induced human embryonic stem cells into primitive neural stem cells (pNSCs) that are self-renewable for massive/transplantable production and can efficiently differentiate into dopamine-like neurons (pNSC-DAn) in culture. Here, we showed that after the striatal transplantation of pNSC-DAn, (i) pNSC-DAn retained tyrosine hydroxylase expression and reduced PD-like asymmetric rotation; (ii) depolarization-evoked dopamine release and reuptake were significantly rescued in the striatum both in vitro (brain slices) and in vivo, as determined jointly by microdialysis-based HPLC and electrochemical carbon fiber electrodes; and (iii) the rescued dopamine was released directly from the grafted pNSC-DAn (and not from injured original cells). Thus, pNSC-DAn grafts release and reuptake dopamine in the striatum in vivo and alleviate PD symptoms in rats, providing proof-of-concept for human clinical translation.